From: Williams, Edwina <edwina.williams@dss.virginia.gov>

Date: Fri, Mar 11, 2022 at 4:09 PM

Subject: Virginia Department of Health Tuberculosis Risk Assessment - Updated Form

To: <DSS\_LICENSING@listserv.cov.virginia.gov>

The attached file is being sent to assisted living facilities and adult day care centers from the Virginia Department of Social Services Email Distribution Service.

\*\*\*Please do not reply to this email.\*\*\*

To unsubscribe from the DSS\_LICENSING list, click the following link: <a href="https://listserv.cov.virginia.gov/scripts/wa.exe?SUBED1=DSS\_LICENSING&A=1">https://listserv.cov.virginia.gov/scripts/wa.exe?SUBED1=DSS\_LICENSING&A=1</a>

# SCROLL DOWN TO VIEW ATTACHMENT



## **DEPARTMENT OF SOCIAL SERVICES**

**DATE:** March 11, 2022

**TO:** Adult Day Care Centers

**Assisted Living Facilities** 

**FROM:** Tara Ragland, Director

Division of Licensing Programs (DOLP)

**SUBJECT:** Virginia Department of Health Tuberculosis Risk Assessment – Updated

This memo is to inform you that the Virginia Department of Health has updated the tuberculosis (TB) risk assessment screening form. The updated document is attached. It can also be accessed on the VDSS public website on ADCC and ALF webpages for your convenience.

Please contact your licensing inspector should you have questions.



# Virginia Department of Health TB Program TB Risk Assessment (TB512)

Protecting You and Your Environment www.vdh.virginia.gov	See Instructions for the TB Risk Assessment for additional information and guidance							
Patient name (L,F,M):			DOB:			Sex:		
Address:				Hispanic or Latino: □No □Yes SSN:				
City, State, ZIP:				Home/Work#:				
Cell#:Language:				Pregnant: □No □Yes □N/A; If yes, LMP				
Country of Birth:	eter ne	needed: □No □Yes Last live vaccine:						
I. Screen for TB Symptoms (Check all that apply)		Yes	Yes No BCG History   Test for TB Infection   TB Treatment					
□None (Skip to Section II)	Pediatric Patients			History of prior BC0	3. Year:			
□Cough for >3 weeks	(< 6 years of age)		]	Positive test for infe				
→Productive: □Yes □No	□Wheezing			Date:				
Hemoptysis	□ Failure to thrive			Treatment for: □LTBI □TB Completed? □Yes □No				
☐ Fever, unexplained	□ Decreased activity,			Location: Dates:				
☐ Unexplained weight loss	playfulness and/or energy			Regimen:				
Poor appetite Evaluate	□Lymph node swelling		Eindi					
□ Night sweats   Evaluate in context			Finding(s) (Check all that apply) Previous treatment for LTBI and/or TB disease					
□Fatigue J	☐Personality changes		□ No risk factors requiring a test for TB infection					
II. Screen for TB Infection Risk (Check all that apply)			☐Risk(s) for TB infection					
Individuals with an increased risk for exposure to TB or for			□Possible presumptive TB disease					
progression to active TB disease once infected should have a test for			☐ Previous positive test for TB infection, no prior treatment					
TB infection.  A. Assess Risk for Exposure to TB								
The Patient			IV. Action(s) (Check all that apply)  □ Issue screening letter					
☐ is a current high risk contact of a person known or presumed to			Refer for CXR					
have TB disease			□Complete a test for TB infection					
□lived in or visited another country where TB is common for 3			☐ Issue sputum containers					
months or more, regardless of length of time in the U.S.			□ Refer for medical evaluation					
☐ is a resident or an employee of a high TB risk congregate setting			Other:					
□is medically underserved								
□ has experienced homelessness within the past two years			□1. IGRA: □QFT □T-SPOT or □TST Lot #:					
$\square$ is an infant, a child, or an adolescent exposed to an adult(s) in high			Date given/drawn:Time:Site: Signature:POS#:					
risk categories			Signature: POS#: POS#:					
□uses injection drugs			TST Reading/IGRA Results					
□ is a member of a group identified by the health department to be at			Date Read:Time:   Signature:POS#:					
an increased risk for TB infection			Induration:mm □Positive □Negative (TST or IGRA)					
□ needs baseline/annual testing approved by the health department			□Borderline □Indeterminate □Invalid (IGRA only)					
B. Assess Risk for Progression to TB Disease if Infected								
ine Patient  □is HIV positive			□2. IGRA: □QFT □T-SPOT or □TST Lot #:					
•			Date given/drawn:Time:Site:					
□ has risk for HIV infection, but HIV status is unknown □ was recently (within past 2 years) infected with <i>Mycobacterium</i>			Signature:POS#: TST Reading/IGRA Results					
tuberculosis			Date Read:Time:					
□ has certain clinical conditions that place them at high risk:			Signature:POS#:					
			Induration:mm □Positive □Negative (TST or IGRA)					
□uses injection drugs			☐Borderline ☐Indeterminate ☐Invalid (IGRA only)					
□has a history of inadequately treated TB		_						
☐is >10% below ideal body weight		Scree	Screener's signature:					
$\Box$ is on immunosuppressive therapy – includes treatment with TNF- $\!\alpha$		Scree	Screener's name (print):					
antagonists (Remicaid, Humira, Enbrel, etc.), other biologic			Date:Phone#:					
response modifiers or prednisone ≥1mo. ≥15mg/day					1 11011011			
	rs, nurses, or nurse practitioners of the nterferon Gamma Release Assay (IGR					berculin Skin Test		
I agree that the results of this test may be shared with other health care providers.								
The Deemed Consent for blood borne diseases has been explained to me and I understand it.								
I acknowledge that I have received the Notice of Privacy Practices from the Virginia Department of Health.								
I understand that:  • this information will be used by health care providers for care and for statistical purposes only.								
<ul> <li>this information will be kept confidential.</li> </ul>								
<ul> <li>medical records must be kept at a minimum for 10 years after my last visit, 5 years after death; for minor children, 5</li> </ul>						inor children, 5		
years after the age of 18, or 10 years after the last visit, whichever is greater.								
X Date:								

November 2021

Client or Parent/Guardian Signature



# Virginia Department of Health TB Program Instructions for the TB Risk Assessment (TB512)

**Purpose of Form** The TB Risk Assessment Form (TB 512) is a tool to assess and document a patient's symptoms and/or risk factors for TB infection. Completing this form will also help in determining the need for future medical testing and evaluation.

<u>Directions for Completing the Form</u>
Print clearly and complete this form
according to instructions provided below.

This form can be adapted for use outside of the Virginia Department of Health (VDH). If using outside of VDH, remove VDH consent section and logo.

#### . Screen for Presence of TB Symptoms

Screen patient for symptoms of active TB disease

- All symptomatic individuals should: (1) receive a test for TB infection if not previously positive (TST or IGRA); (2) have their sputum collected; (3) be referred for an immediate chest x-ray (CXR) and medical evaluation, regardless of the result of the test for TB infection.
- If patient does not have symptoms of active TB disease, go to Section II and assess risk for LTBI and/or disease.
- Symptoms of active TB disease are more subtle in children. Children with symptoms of active TB disease should receive a test for TB infection, CXR (PA and lateral views for children under 5) and immediate medical evaluation by medical personnel knowledgeable about pediatric TB.

## II. Screen for TB Infection Risk (In subsections A and B, check all the risk factors that apply)

Section II has 2 sections. Section A: "Assess Risk for Exposure to TB", Section B: "Assess Risk for Progression to TB Disease if Infected".

- If patient has one or more risk factors as listed in sections II A or II B, then go to Section III and administer a test for TB infection.
- If patient does not have risk factors for exposure to TB or progression to TB disease, do not administer a test for TB infection. Go to Section III and place a check next to "No Risk Factors for TB Infection."
- If patient's school, employment, etc. requires a TB screening, place a check next to "Issued Screening Letter" (Section IV) and provide the screening letter to the patient.

#### A. Assess Risk for Exposure to TB

- Current high risk contact of a person known or presumed to have TB disease-Person is part of a current TB contact investigation
- Person lived in or visited another country where TB is common for 3 months or more, regardless of time in the U.S.-- Person lived or visited a high TB endemic country ≥ 3 months. High endemic country is defined as a case rate of ≥ 20/100,000. See VDH list for high TB endemic countries. Evaluate other time (≤3 months) spent in high TB endemic countries in context. Example: volunteering in a medical setting for 1 month would trigger testing.
- Person is a resident/employee of high TB risk congregate settings--These settings are homeless shelters, correctional facilities, nursing homes, and long-term care facilities.
- Person is medically underserved-- Person doesn't have a regular healthcare provider, and has not received medical care within the last 2 years.
- Person is an infant, a child or an adolescent exposed to an adult(s) in high-risk categories-- Child has non-U.S.-born parents from a high TB endemic country, or child's parents/caretakers are at high risk for exposure to TB.
- Person is a member of a group identified by a local health department to be at an
  increased risk for TB infection--Identification of a group is based on local
  epidemiologic data showing an increase in the number of persons with TB disease or
  TB infection in the given group.
- Person needs baseline/annual testing approved by health department-- includes those
  entering health professions; new healthcare workers need 2-step TST unless
  documented negative TST in prior 12 months. Single IGRA also acceptable. May
  include a screening program that is approved by the local health dept. for facilities or
  individuals at an increased risk for exposure to TB.

#### Assess Risk for Progression to TB Disease if Infected

- Person's HIV status is unknown but has risk for HIV infection-- Offer HIV test.
   Administer test for TB infection, even if the patient declines the HIV test.
- Person with clinical conditions that place them at high risk-- Conditions include substance use, CXR findings that suggest previous TB, diabetes mellitus, silicosis, prolonged corticosteroid therapy, cancer of the head and neck, leukemia, lymphoma, hematologic and reticuloendothelial diseases, end stage renal disease, intestinal bypass or gastrectomy, and chronic malabsorption syndromes.
- Person is on immunosuppressive therapy-- Examples: Post solid organ transplant; taking ≥ 15 mg/day of prednisone for ≥ 1 month; receiving treatment with TNF-α antagonists (Remicaid, Humira, Enbrel, etc.) or other biologic response modifiers and/or needs baseline evaluation prior to start of treatment with such meds.

#### III. Finding(s)

In this section, indicate findings from the assessments in all previous sections.

#### IV. Action(s)

- Indicate the action(s) to take as a result of the findings in Section III.
- If administering a test for TB infection, provide all requested data.
- Repeat test for TB infection if appropriate.

#### Additional follow-up to a test for TB infection

- · If test for TB infection is positive, or patient has symptoms suggestive of TB disease, refer immediately for medical evaluation and CXR
- If history of a positive test for TB infection and currently asymptomatic, refer for CXR if the following two conditions apply:
- 1) patient is a candidate for LTBI treatment; **and**, 2) patient is willing to adhere to the treatment.
- If treatment for LTBI is not planned and TB previously ruled out with a normal CXR, then repeat CXRs are not indicated unless symptomatic.

#### Considerations

- Tests for TB infection should be administered at the same time as live viral vaccine administration, or after 4-6 weeks, as defined by the AAP (Red Book) and ACIP, with 6 weeks being the ideal time period to wait based upon these recommended time frames. However, 4 weeks (28 days), as outlined in the Pink Book and NTCA Testing and Treatment of LTBI in the US: Clinical Recommendations is a satisfactory time interval.
- COVID-19 vaccine does not interfere with timing of testing for TB infection
- IGRA is recommended for use in children 2 years of age and older. Consider the use of IGRA in those younger than 2 with expert medical consultation.
- TST can be used in any age group.
- IGRA is the preferred test for TB infection in BCG vaccinated individuals.
- Repeat testing for TB infection should be based on new risk factors or clinical information.